ATAD2 and lung carcinoma: Recently, a number of reports have demonstrated that expression of ATAD2 strongly correlates with poor prognosis in different unrelated tumors including gastric cancer [15], endometrial carcinoma [16], hepatocellular carcinoma [17], ovarian carcinoma [18], breast cancer [11, 19] and lung cancer [11] and hence proposed ATAD2 as a poor prognostic marker.